A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients

M. Mori, H. Nisimura, A. Urabe, K. Tamura, S. Makino, K. Okabe, J. Tomiyama, M. Hara, M. Tanimoto, M. Kikuchi, H. Hamaguchi, H. Sato, Y. Saburi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Twenty-nine patients aged 60-75 years with newly diagnosed acute myelogenous leukemia (AML) were randomized to receive BHAC-DM either at a reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day) or the conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day). On day 7, patients were given therapy for 2 more days if the ratio of blasts in their bone marrow was more than 15%. Granulocyte-colony stimulating factor was injected when the leukocyte count decreased below 1,000/microliter. The rates of complete remission were 46.2% in the S-1 group and 43.8% in the S-2 group. No significant differences in response distinguished the 2 groups. The mortality rate during myelosuppression was 1/13 in the S-1 group and 1/16 in the S-2 group. The rate of treatment-related death was 10.1% for all patients. Grade-4 adverse effects were not seen in any of the patients. We concluded that the conventional dose of BHAC-DM was as acceptable as the reduced dose in elderly patients with AML.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume41
Issue number2
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Therapeutics
Granulocyte Colony-Stimulating Factor
Leukocyte Count
Bone Marrow
Mortality

Cite this

A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients. / Mori, M.; Nisimura, H.; Urabe, A.; Tamura, K.; Makino, S.; Okabe, K.; Tomiyama, J.; Hara, M.; Tanimoto, M.; Kikuchi, M.; Hamaguchi, H.; Sato, H.; Saburi, Y.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 41, No. 2, 2000, p. 109-114.

Research output: Contribution to journalArticle

Mori, M, Nisimura, H, Urabe, A, Tamura, K, Makino, S, Okabe, K, Tomiyama, J, Hara, M, Tanimoto, M, Kikuchi, M, Hamaguchi, H, Sato, H & Saburi, Y 2000, 'A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 41, no. 2, pp. 109-114.
Mori, M. ; Nisimura, H. ; Urabe, A. ; Tamura, K. ; Makino, S. ; Okabe, K. ; Tomiyama, J. ; Hara, M. ; Tanimoto, M. ; Kikuchi, M. ; Hamaguchi, H. ; Sato, H. ; Saburi, Y. / A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 2000 ; Vol. 41, No. 2. pp. 109-114.
@article{ea3c5606846749949e89fde023010819,
title = "A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients",
abstract = "Twenty-nine patients aged 60-75 years with newly diagnosed acute myelogenous leukemia (AML) were randomized to receive BHAC-DM either at a reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day) or the conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day). On day 7, patients were given therapy for 2 more days if the ratio of blasts in their bone marrow was more than 15{\%}. Granulocyte-colony stimulating factor was injected when the leukocyte count decreased below 1,000/microliter. The rates of complete remission were 46.2{\%} in the S-1 group and 43.8{\%} in the S-2 group. No significant differences in response distinguished the 2 groups. The mortality rate during myelosuppression was 1/13 in the S-1 group and 1/16 in the S-2 group. The rate of treatment-related death was 10.1{\%} for all patients. Grade-4 adverse effects were not seen in any of the patients. We concluded that the conventional dose of BHAC-DM was as acceptable as the reduced dose in elderly patients with AML.",
author = "M. Mori and H. Nisimura and A. Urabe and K. Tamura and S. Makino and K. Okabe and J. Tomiyama and M. Hara and M. Tanimoto and M. Kikuchi and H. Hamaguchi and H. Sato and Y. Saburi",
year = "2000",
language = "English",
volume = "41",
pages = "109--114",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "2",

}

TY - JOUR

T1 - A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients

AU - Mori, M.

AU - Nisimura, H.

AU - Urabe, A.

AU - Tamura, K.

AU - Makino, S.

AU - Okabe, K.

AU - Tomiyama, J.

AU - Hara, M.

AU - Tanimoto, M.

AU - Kikuchi, M.

AU - Hamaguchi, H.

AU - Sato, H.

AU - Saburi, Y.

PY - 2000

Y1 - 2000

N2 - Twenty-nine patients aged 60-75 years with newly diagnosed acute myelogenous leukemia (AML) were randomized to receive BHAC-DM either at a reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day) or the conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day). On day 7, patients were given therapy for 2 more days if the ratio of blasts in their bone marrow was more than 15%. Granulocyte-colony stimulating factor was injected when the leukocyte count decreased below 1,000/microliter. The rates of complete remission were 46.2% in the S-1 group and 43.8% in the S-2 group. No significant differences in response distinguished the 2 groups. The mortality rate during myelosuppression was 1/13 in the S-1 group and 1/16 in the S-2 group. The rate of treatment-related death was 10.1% for all patients. Grade-4 adverse effects were not seen in any of the patients. We concluded that the conventional dose of BHAC-DM was as acceptable as the reduced dose in elderly patients with AML.

AB - Twenty-nine patients aged 60-75 years with newly diagnosed acute myelogenous leukemia (AML) were randomized to receive BHAC-DM either at a reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day) or the conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day). On day 7, patients were given therapy for 2 more days if the ratio of blasts in their bone marrow was more than 15%. Granulocyte-colony stimulating factor was injected when the leukocyte count decreased below 1,000/microliter. The rates of complete remission were 46.2% in the S-1 group and 43.8% in the S-2 group. No significant differences in response distinguished the 2 groups. The mortality rate during myelosuppression was 1/13 in the S-1 group and 1/16 in the S-2 group. The rate of treatment-related death was 10.1% for all patients. Grade-4 adverse effects were not seen in any of the patients. We concluded that the conventional dose of BHAC-DM was as acceptable as the reduced dose in elderly patients with AML.

UR - http://www.scopus.com/inward/record.url?scp=0034132901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034132901&partnerID=8YFLogxK

M3 - Article

C2 - 10723239

AN - SCOPUS:0034132901

VL - 41

SP - 109

EP - 114

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 2

ER -